{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:59:18Z","timestamp":1776329958981,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Consistent reports from health professionals suggest that heroin is commonly used by patients undergoing opioid maintenance treatment (OMT) in France, potentially jeopardizing their recovery process. However, there has been no formal epidemiological assessment on the matter.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We use a yearly updated compendium retrieving information on patients admitted in treatment centres in France between 2010 and 2020. Given the hierarchical nature of the data collection, we conduct 2-level modified Poisson regressions to estimate the risks of past month heroin use among patients on OMT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Despite an overall decreasing trend over time, heroin use among patients on OMT is indeed common, with half of patients declaring concurrent use. Our study unveils differentiated risks of heroin use vary according to the type of OMT, with patients on methadone more likely to use heroin compared to those on buprenorphine. The use of multilevel-related measures also uncovers high heterogeneity among patients\u2019 profiles, reflecting different stages in the treatment process, as well as differentiated practices across treatment centres.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Opioid maintenance treatment is associated with heroin use, in particular when methadone is involved. The heterogeneity among patients on OMT should be given particular attention, as it underscores the need for tailored interventions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00934-x","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T13:02:17Z","timestamp":1705669337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors of concurrent heroin use among patients on opioid maintenance treatment in France: a multilevel study over 11\u00a0years"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-9657","authenticated-orcid":false,"given":"Eric","family":"Janssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Vuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Spilka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Airagnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109445","volume":"235","author":"OK Golan","year":"2022","unstructured":"Golan OK, Totaram R, Perry E, Fortson K, Rivera-Atilano R, Entress R, et al. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug Alcohol Depend. 2022;235: 109445.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"934_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000514192","volume":"27","author":"SPE Guillery","year":"2021","unstructured":"Guillery SPE, Hellweg R, Kronenberg G, Bohr U, Kunte H, Enge S. Quality of life in opioid replacement therapy: a naturalistic cross-sectional comparison of methadone\/levomethadone, buprenorphine, and diamorphine patients. Eur Addict Res. 2021;27(5):371\u201380.","journal-title":"Eur Addict Res"},{"issue":"1\u20132","key":"934_CR3","first-page":"55","volume":"63","author":"VP Dole","year":"1968","unstructured":"Dole VP, Nyswander ME. The use of methadone for narcotic blockade. Br J Addict. 1968;63(1\u20132):55\u20137.","journal-title":"Br J Addict"},{"issue":"19","key":"934_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1001\/jama.1976.03260450029025","volume":"235","author":"VP Dole","year":"1976","unstructured":"Dole VP, Nyswander ME. Methadone maintenance treatment: a ten-year perspective. JAMA. 1976;235(19):2117\u20139.","journal-title":"JAMA"},{"issue":"1","key":"934_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ajem.2018.10.013","volume":"37","author":"DH Cisewski","year":"2019","unstructured":"Cisewski DH, Santos C, Koyfman A, Long B. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting. Am J Emerg Med. 2019;37(1):143\u201350.","journal-title":"Am J Emerg Med"},{"issue":"6","key":"934_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","volume":"39","author":"M Olfson","year":"2020","unstructured":"Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others. Health Aff. 2020;39(6):984\u201392.","journal-title":"Health Aff"},{"issue":"1","key":"934_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/10550887.2012.759872","volume":"32","author":"AM Neumann","year":"2013","unstructured":"Neumann AM, Blondell RD, Jaanim\u00e4gi U, Giambrone AK, Homish GG, Lozano JR, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013;32(1):68\u201378.","journal-title":"J Addict Dis"},{"issue":"1","key":"934_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0976-3147.91934","volume":"3","author":"PJ Whelan","year":"2012","unstructured":"Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45\u201350.","journal-title":"J Neurosci Rural Pract"},{"key":"934_CR9","doi-asserted-by":"crossref","unstructured":"Tanz LJ, Jones CM, Davis NL, Compton WM, Baldwin GT, Han B, et al. Trends and characteristics of buprenorphine-involved overdose deaths prior to and during the COVID-19 pandemic. JAMA Netw Open. 2023;6(1):e2251856-e.","DOI":"10.1001\/jamanetworkopen.2022.51856"},{"issue":"5","key":"934_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","volume":"9","author":"M Fatseas","year":"2007","unstructured":"Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9(5):358\u201364.","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"934_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0740-5472(01)00189-1","volume":"21","author":"J Vignau","year":"2001","unstructured":"Vignau J, Duhamel A, Catteau J, Legal G, Pho AH, Grailles I, et al. Practice-based buprenorphine maintenance treatment (BMT): How do French healthcare providers manage the opiate-addicted patients? J Subst Abuse Treat. 2001;21(3):135\u201344.","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"934_CR12","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/j.1360-0443.2005.01271.x","volume":"100","author":"J Emmanuelli","year":"2005","unstructured":"Emmanuelli J, Desenclos J-C. Harm reduction interventions, behaviours and associated health outcomes in France, 1996\u20132003. Addiction. 2005;100(11):1690\u2013700.","journal-title":"Addiction"},{"issue":"10","key":"934_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"934_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1108\/DHS-04-2022-0019","volume":"24","author":"BC Kelly","year":"2023","unstructured":"Kelly BC, Vuolo M. Correlates of heroin use, pharmaceutical fentanyl misuse, and dual heroin-fentanyl use: evidence from the U.S. Drugs Habits Soc Policy. 2023;24(1):14\u201325.","journal-title":"Drugs Habits Soc Policy"},{"issue":"5","key":"934_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/dar.12355","volume":"35","author":"E Lahaie","year":"2015","unstructured":"Lahaie E, Janssen E, Cadet-Ta\u00efrou A. Determinants of heroin retail prices in metropolitan France: discounts, purity and local markets. Drug Alcohol Rev. 2015;35(5):597\u2013604.","journal-title":"Drug Alcohol Rev"},{"key":"934_CR16","unstructured":"Gandilhon M, Cadet-Ta\u00efrou A, Laz\u00e8s-Charmetant A, Zurbach E, Schl\u00e9ret Y, Pavic G, et al. Substance uses in rural areas. Population, markets, public responses [Les usages de drogues en espace rural : populations, march\u00e9s, r\u00e9ponse publique]. Tendances. OFDT; 2015(104)."},{"issue":"2","key":"934_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.addbeh.2017.10.013","volume":"77","author":"F Heidebrecht","year":"2018","unstructured":"Heidebrecht F, MacLeod MB, Dawkins L. Predictors of heroin abstinence in opiate substitution therapy in heroin-only users and dual users of heroin and crack. Addict Behav. 2018;77(2):210\u20136.","journal-title":"Addict Behav"},{"key":"934_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.drugpo.2018.02.020","volume":"55","author":"T Hoang","year":"2018","unstructured":"Hoang T, Nguyen H, Shiraishi RW, Nguyen M, Bingham T, Nguyen D, et al. Factors associated with concurrent heroin use among patients on methadone maintenance treatment in Vietnam: a 24-month retrospective analysis of a nationally representative sample. Int J Drug Policy. 2018;55:113\u201320.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"934_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12954-023-00872-0","volume":"20","author":"HTT Nguyen","year":"2023","unstructured":"Nguyen HTT, Dinh DX. Opioid relapse and its predictors among methadone maintenance patients: a multicenter, cross-sectional study in Vietnam. Harm Reduct J. 2023;20(1):136.","journal-title":"Harm Reduct J"},{"key":"934_CR20","unstructured":"OECD. Addressing problematic opioid Use in OECD Countries. Paris: OECD; 2019."},{"issue":"5","key":"934_CR21","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/ejp.1728","volume":"25","author":"T Seyler","year":"2021","unstructured":"Seyler T, Giraudon I, Noor A, Mounteney J, Griffiths P. Is Europe facing an opioid epidemic: What does European monitoring data tell us? Eur J Pain. 2021;25(5):1072\u201380.","journal-title":"Eur J Pain"},{"issue":"1","key":"934_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12954-022-00608-6","volume":"19","author":"LM Guillou","year":"2022","unstructured":"Guillou LM, Dany A, Challet BG, Laforgue EJ, Cholet J, Leboucher J, et al. How do people who use drugs receiving Opioid Medication Therapy perceive their treatment\u202f? A multicentre study. Harm Reduct J. 2022;19(1):31.","journal-title":"Harm Reduct J"},{"issue":"3","key":"934_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/10550887.2011.581985","volume":"30","author":"LM Carcoba","year":"2011","unstructured":"Carcoba LM, Contreras AE, Cepeda-Benito A, Meagher MW. Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals. J Addict Dis. 2011;30(3):258\u201370.","journal-title":"J Addict Dis"},{"issue":"3","key":"934_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00213-009-1472-0","volume":"204","author":"ZY Ren","year":"2009","unstructured":"Ren ZY, Shi J, Epstein DH, Wang J, Lu L. Abnormal pain response in pain-sensitive opiate addicts after prolonged abstinence predicts increased drug craving. Psychopharmacology. 2009;204(3):423\u20139.","journal-title":"Psychopharmacology"},{"key":"934_CR25","unstructured":"EMCDDA. Treatment demand indicator (TDI) Standard protocol 3.0. Guidelines for reporting data on people entering drug treatment in European countries. Luxembourg: EMCDDA; 2012."},{"issue":"7","key":"934_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702\u20136.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"934_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/sim.7532","volume":"37","author":"PC Austin","year":"2018","unstructured":"Austin PC, Stryhn H, Leckie G, Merlo J. Measures of clustering and heterogeneity in multilevel Poisson regression analyses of rates\/count data. Stat Med. 2018;37(4):572\u201389.","journal-title":"Stat Med"},{"key":"934_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/SAR.S221618","volume":"11","author":"SL Carlsen","year":"2020","unstructured":"Carlsen SL, Lunde LH, Torsheim T. Opioid and polydrug use among patients in opioid maintenance treatment. Subst Abus Rehab. 2020;11:9\u201318.","journal-title":"Subst Abus Rehab"},{"key":"934_CR29","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014(2):Cd002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"issue":"9358","key":"934_CR30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","volume":"361","author":"J Kakko","year":"2003","unstructured":"Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662\u20138.","journal-title":"Lancet"},{"key":"934_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1196\/annals.1441.030","volume":"1141","author":"R Sinha","year":"2008","unstructured":"Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141:105\u201330.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"934_CR32","first-page":"311","volume":"32","author":"J Selin","year":"2015","unstructured":"Selin J, Per\u00e4l\u00e4 R, Stenius K, Partanen A, Rosenqvist P, Alho H. Opioid substitution treatment in Finland and other Nordic countries: established treatment, varying practices. Nordisk Alkohol Nark. 2015;32(3):311\u201324.","journal-title":"Nordisk Alkohol Nark"},{"key":"934_CR33","unstructured":"Cadet-Ta\u00efrou A, Janssen E, Guilbauld F. Clients serviced in harm reduction facilities in 2019. Profiles and practices [Profils et pratiques des usagers des CAARUD en 2019]. Tendances. OFDT; 2020(142):1\u20134."},{"issue":"1","key":"934_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13011-021-00417-3","volume":"16","author":"L Garpenhag","year":"2021","unstructured":"Garpenhag L, Dahlman D. Perceived healthcare stigma among patients in opioid substitution treatment: a qualitative study. Subst Abus Treat Prev Pol. 2021;16(1):81.","journal-title":"Subst Abus Treat Prev Pol"},{"issue":"2","key":"934_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/09687637.2012.743506","volume":"20","author":"C Lloyd","year":"2013","unstructured":"Lloyd C. The stigmatization of problem drug users: a narrative literature review. Drugs Educ Prev Policy. 2013;20(2):85\u201395.","journal-title":"Drugs Educ Prev Policy"},{"issue":"1","key":"934_CR36","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/08897077.2021.1975872","volume":"43","author":"AR Brown","year":"2022","unstructured":"Brown AR. Health professionals\u2019 attitudes toward medications for opioid use disorder. Subst Abus. 2022;43(1):598\u2013614.","journal-title":"Subst Abus"},{"issue":"1","key":"934_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1331\/1544345052843200","volume":"45","author":"DW Raisch","year":"2005","unstructured":"Raisch DW, Fudala PJ, Saxon AJ, Walsh R, Casadonte P, Ling W, et al. Pharmacists\u2019 and technicians\u2019 perceptions and attitudes toward dispensing buprenorphine\/naloxone to patients with opioid dependence. J Am Pharm Assoc. 2005;45(1):23\u201332.","journal-title":"J Am Pharm Assoc"},{"issue":"1\u20132","key":"934_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1\u20132):23\u201335.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"934_CR39","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/scan\/nsz094","volume":"14","author":"P Bach","year":"2019","unstructured":"Bach P, Frischknecht U, Klinkowski S, Bungert M, Karl D, Vollmert C, et al. Higher social rejection sensitivity in opioid-dependent patients is related to smaller insula gray matter volume: a voxel-based morphometric study. Soc Cogn Affect Neurosci. 2019;14(11):1187\u201395.","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"3","key":"934_CR40","volume":"8","author":"BX Tran","year":"2018","unstructured":"Tran BX, Boggiano VL, Thi Nguyen HL, Nguyen LH, Nguyen HV, Hoang CD, et al. Concurrent drug use among methadone maintenance patients in mountainous areas in northern Vietnam. BMJ. 2018;8(3): e015875.","journal-title":"BMJ"},{"issue":"1","key":"934_CR41","doi-asserted-by":"publisher","first-page":"1565624","DOI":"10.1080\/23311908.2019.1565624","volume":"6","author":"S-EL Carlsen","year":"2019","unstructured":"Carlsen S-EL, Lunde L-H, Torsheim T. Predictors of quality of life of patients in opioid maintenance treatment in the first year in treatment. Cogent Psychol. 2019;6(1):1565624.","journal-title":"Cogent Psychol"},{"issue":"1","key":"934_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1037\/0021-9010.93.1.199","volume":"93","author":"MR Frone","year":"2008","unstructured":"Frone MR. Are work stressors related to employee substance use? The importance of temporal context assessments of alcohol and illicit drug use. J Appl Psychol. 2008;93(1):199\u2013206.","journal-title":"J Appl Psychol"},{"key":"934_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.socscimed.2015.08.016","volume":"143","author":"JO Lee","year":"2015","unstructured":"Lee JO, Hill KG, Hartigan LA, Boden JM, Guttmannova K, Kosterman R, et al. Unemployment and substance use problems among young adults: Does childhood low socioeconomic status exacerbate the effect? Soc Sci Med. 2015;143:36\u201344.","journal-title":"Soc Sci Med"},{"issue":"7","key":"934_CR44","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/10826080701409644","volume":"42","author":"L Schmidt","year":"2007","unstructured":"Schmidt L, Zabkiewicz D, Jacobs L, Wiley J. Substance abuse and employment among welfare mothers: from welfare to work and back again? Subst Use Misuse. 2007;42(7):1069\u201387.","journal-title":"Subst Use Misuse"},{"key":"934_CR45","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/978-1-4899-7627-7_36","volume-title":"Handbook of return to work: from research to practice","author":"L Richardson","year":"2016","unstructured":"Richardson L, Epp S. Substance use disorders, employment and the return to work. In: Schultz IZ, Gatchel RJ, editors. Handbook of return to work: from research to practice. Boston: Springer; 2016. p. 667\u201392."},{"key":"934_CR46","first-page":"24","volume":"3","author":"F Beck","year":"2013","unstructured":"Beck F, Guignard R, Gautier A, Palle C, Obradovic I. Treatment and care of opioid users by general practitioners: current situation and trends [La prise en charge des usagers d\u2019opiac\u00e9s par les m\u00e9decins g\u00e9n\u00e9ralistes\u202f: \u00e9tat des lieux et tendances r\u00e9centes]. Rev Fr Aff Soc. 2013;3:24\u201341.","journal-title":"Rev Fr Aff Soc"},{"key":"934_CR47","unstructured":"Conseil National de l'Ordre des M\u00e9decins, Ordre des Pharmaciens. Recommandations des Conseils Nationaux de l'Ordre des Pharmaciens et des M\u00e9decins \u00e0 propos de la prescription et de la dispensation des m\u00e9dicaments de substitution aux opiac\u00e9s. Paris; 2017."},{"issue":"2","key":"934_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/08897077.2019.1573776","volume":"40","author":"HB Ward","year":"2019","unstructured":"Ward HB, Barnett BS, Suzuki J. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: a case report. Subst Abus J. 2019;40(2):140\u20135.","journal-title":"Subst Abus J"},{"issue":"2","key":"934_CR49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/ADM.0000000000000855","volume":"16","author":"N Lintzeris","year":"2022","unstructured":"Lintzeris N, Mankabady B, Rojas-Fernandez C, Amick H. Strategies for transfer from methadone to buprenorphine for treatment of opioid use disorders and associated outcomes: a systematic review. J Addict Med. 2022;16(2):66.","journal-title":"J Addict Med"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00934-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00934-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00934-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T17:05:49Z","timestamp":1705683949000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00934-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00934-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"18 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey was approved by an internal steering committee which acts as the equivalent of an Institutional Review Board and the National Data Protection Authority (CNIL). As part of official medical records that are a mandatory requirement for the Ministry of Health and required by patients to comply with, the survey does not include an explicit consent process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}